Amgen: Multiple Strengths, But The Valuation Is A Concern
Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...
Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating
Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...
Hosted on MSN2mon
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
Amgen said its experimental weight loss injection ... how quickly people who lost weight rebound when they come off the medicine," Bradner said in the interview. The second part of the trial ...
Amgen profits rise, next MariTide studies start by mid-year
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...
pharmaphorum5d
Chasing Novartis, Amgen ushers Lp(a) drug into phase 3
Amgen has reported encouraging mid-stage results ... Final results of the OCEAN(a)-DOSE trial – published in the New England Journal of Medicine – showed that the small, interfering RNA ...